Agios Pharmaceuticals | AGIO - Equity Capital And Reserves


Agios Pharmaceuticals reported $1.11B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
Astellas Pharma JPY 1.83T 65.92B Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Exelixis USD 1.94B 225.57M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026